Mark Douglas Smith News Today

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $18.15-$19.35 for the period, compared to the consensus estimate of $19.94. The company issued revenue guidance of $4.0-$4.2 billion, compared to the consensus revenue estimate of $4.08 billion. Jazz Pharmaceuticals also updated […]

Aristotle Capital Management LLC purchased a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 175,757 shares of the specialty pharmaceutical company’s stock, valued at approximately $22,748,000. Aristotle Capital […]

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its target price cut by JPMorgan Chase & Co. from $180.00 to $170.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside […]

PNC Financial Services Group Inc. cut its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 36.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,807 shares of the specialty pharmaceutical company’s stock after selling 2,737 shares during the quarter. PNC […]

Rhenman & Partners Asset Management AB decreased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 0.9% in the 3rd quarter, HoldingsChannel reports. The firm owned 143,634 shares of the specialty pharmaceutical company’s stock after selling 1,366 shares during the quarter. Jazz Pharmaceuticals makes up 2.0% of Rhenman & Partners Asset Management AB’s […]

Barclays PLC increased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 9.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 99,366 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,834 shares during the […]

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its price objective dropped by Barclays from $240.00 to $235.00 in a research report issued on Monday, Benzinga reports. The firm currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Barclays‘s price target would suggest a potential upside of 87.16% from the company’s previous close. […]

Retirement Systems of Alabama reduced its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 2.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 172,931 shares of the specialty pharmaceutical company’s stock after selling 3,651 shares during the quarter. Retirement […]

Retirement Systems of Alabama reduced its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 2.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 172,931 shares of the specialty pharmaceutical company’s stock after selling 3,651 shares during […]

Segantii Capital Management Ltd acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) in the third quarter, HoldingsChannel.com reports. The fund acquired 25,300 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,275,000. Several other hedge funds also recently made changes to their positions in the company. Aviance Capital […]